Anastasia Zherlitsyna — timeline

Metastatic GIST (initially diagnosed as uterine leiomyosarcoma), Kyiv, Ukraine · records 2022–2026 · updated 14 Oct 2026

← labs and other records

D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018

Date: 2018-01-19   Category: publication   Language: en
Drive path: immunotherapy_suggestion/10.1016@S1470-20451830006-8.pdf

Links: this document on Google Drive [hosted copy]
Summary: Journal article (Lancet Oncology, 2018) reporting two phase 2 trials of nivolumab with or without ipilimumab in metastatic sarcoma, cited as supporting literature for an immunotherapy second opinion.
D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018
D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018
D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018
D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018
D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018
D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018
D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018
D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018
D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018
D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018
D'Angelo et al., Nivolumab with or without ipilimumab for metastatic sarcoma (Alliance A091401), Lancet Oncol 2018